ロード中...
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
BACKGROUND: Guselkumab is an interleukin‐23 inhibitor indicated for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long‐term efficacy comparisons of guselkumab and ustekinumab a...
保存先:
| 出版年: | Br J Dermatol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496582/ https://ncbi.nlm.nih.gov/pubmed/31652347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18634 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|